Oral-health probiotic strain BLIS M18 gets FDA No Objection GRAS letter

The AHPA ERB Foundation is sponsoring a supply chain assessment of the myrrh trade to better understand harvesting practices and more directly engage with the people harvesting this important botanical.

Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?

The hydration category and ingredients within the category are continuing to see immense growth as a broader range of consumers see the value in hydration products for daily maintenance and well-being.

In the supplemental submission CRN urged FDA to reexamine and correct its interpretation of the drug preclusion clause rather than provide justification for its interpretation

On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”

U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.